Arovella Therapeutics Limited (ALA)의 가격은 얼마입니까?

Arovella Therapeutics Limited (ALA)의 가격은 $0.04584351입니다.

Arovella Therapeutics Limited (ALA)의 시가 총액은 무엇입니까?

Arovella Therapeutics Limited (ALA)의 시가 총액은 $55.42M입니다.

Arovella Therapeutics Limited (ALA) 주당순이익

Arovella Therapeutics Limited, an Australian biotechnology firm, is dedicated to developing therapeutic solutions for oncology and central nervous system afflictions, operating both domestically and internationally. Its pipeline features several key assets, including ZolpiMist, an oral spray formulation of zolpidem tartrate for the treatment of short-term insomnia, commercially known by brands such as Ambien or Stilnox. The company is also advancing an invariant natural killer T (iNKT) cell therapy platform specifically designed to target blood cancers. Furthermore, Arovella employs OroMist, an oro-mucosal technology enabling the delivery of various drug classes through absorption in the oral cavity via the cheeks, gums, tongue, or mouth floor, and is developing Anagrelide for cancer treatment. Beyond these, the company is engaged in creating oral sprays to address conditions like migraine headaches, motion sickness, and drug-resistant epilepsy. Arovella maintains a research collaboration agreement with Imperial College London. Established in 1999 and based in Osborne Park, Australia, the company was formerly known as Suda Pharmaceuticals Ltd before rebranding to Arovella Therapeutics Limited in October 2021.

연도	EPS	변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.

연도

EPS

변화

제공된 날짜에 대한 데이터가 충분하지 않습니다.

회사	EPS	EPS 차이	국가
Vertex Pharmaceuticals Incorporated VRTX.US	$17.32	-	US
Argenx SE ARGX.US	$27.74	-	NL
CSL Limited CSL.AX	$2.98	-	AU
Lonza Group AG LONN.SW	-	-	CH
Moderna, Inc. MRNA.US	$-7.98	-	US

회사

EPS

EPS 차이

국가